Abstract
Prostate cancer is a major public health problem becoming one of the most common cancers in males, affecting 1 in 6 men in developed counties. Prostate cancer is age-related and is uncommon before the age of 50. After this age, the incidence and mortality rates increase exponentially. Nowadays, due to prostate specific antigen (PSA) testing, about 70% of prostate cancers are diagnosed at an early curable stage. Prostate cancer survival rates have been improving over the last 25 years, probably due to stage/grade migration, public awareness and considerable improvement in therapeutic management. Age plays a major role in decision-making of therapeutic modalities, and a 10-year life expectancy is broadly accepted among urologists and radiation oncologists, because of the natural history of prostate cancer, for a curative treatment intent. However, no age cut-off is warrantable, because of statistical increase in life expectancy and better treatment of co-morbidities. Nevertheless, patients with poorly differentiated prostate cancers are at high risk of death even at an older age.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
